САХИН Угур (DE),КРАЙТЕР Себастьян (DE),ДИКЕН Мустафа (DE),ДИКМАНН Ян (DE),КОЗЛОВСКИ Михаель (DE),БРИТТЕН Цедрик (DE),КЭСТЛ Джон (DE),ЛЁВЕР Мартин (DE),РЕНАРД Бернхард (DE),ОМОКОКО Тана (DE),ДЕ ГРАФ Йо
申请号：
RU2013157150/15
公开号：
RU2013157150A
申请日:
2012.05.23
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A method of obtaining an individual antitumor vaccine, comprising the steps of: (a) identifying tumor-specific somatic mutations in a tumor sample of a cancer patient to obtain a signature of the tumor mutations of the patient； and (b) obtaining a vaccine that is characterized by the signature of the tumor mutations obtained in stage (a). 2. The method of claim 1, wherein the step of identifying the tumor-specific somatic mutations comprises identifying the signature of the tumor mutations of the exoma of one or more cancer cells. The method of claim 1, wherein the step of identifying tumor-specific somatic mutations involves sequencing the genome of one cell from one or more cancer cells. The method of claim 3, wherein the cancer cells are circulating tumor cells. The method of claim 1, wherein the step of identifying tumor-specific somatic mutations involves the use of next-generation sequencing (NGS). The method of claim 1, wherein the step of identifying the tumor-specific somatic mutations involves sequencing the genomic DNA and / or RNA of the tumor sample. The method of claim 6, wherein the step of identifying tumor-specific somatic mutations is repeated at least twice. The method of claim 1, further comprising the step of determining the suitability of the identified mutations in the epitopes for antitumor vaccination. The method of claim 1, wherein the vaccine, the signature of which is the signature of a patient's tumor mutations, comprises a polypeptide comprising mutation-based neoepitopes or a nucleic acid encoding the polypeptide. The method according to claim 9, where the polypeptide includes up to 30 neoepitopes based on m1. Способ получения индивидуальной противоопухолевой вакцины, включающий стадии:(a) идентификации опухолеспецифичных соматических мутаций в образце опухоли онкопациента с получением сигнатуры опухолевых мутаций пациента； и(b) получения вакцины, характерной чертой которой является сигнатура опухолевых мутаций, полученная в стадии
